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Abstract: Background: NICOLAS is the first completed single-arm phase II trial in stage III NSCLC
examining hierarchically first the safety and then the efficacy of adding nivolumab concurrently to stan-
dard definitive concurrent chemo-radiotherapy. The safety endpoint was reported earlier; here we present
the efficacy results. Methods: Stage IIIA/B unresectable treatment-naive NSCLC patients received
3 cycles of platinum-based chemotherapy and concurrent radiotherapy (66Gy/33fractions), along with
nivolumab (360mg/Q3W). Nivolumab was continued as monotherapy consolidation for a maximum of
one year (480mg/Q4W). The primary endpoint was 1-year PFS, with a target improvement compared to
historical data of at least 15%, from 45% to 60%. For testing this efficacy hypothesis, a sample size of 74
evaluable patients provides power 83%, at 1-sided alpha 5%. Findings: 79 patients were enrolled with me-
dian follow-up 21.0 months (m) (Interquartile Range:15.8m-25.8m) for the primary PFS analysis. 35.4%
of patients had stage IIIA and 63.3% stage IIIB. The 1-year PFS was 53.7% (95%CI[42.0%-64.0%]),
the median PFS 12.7m (95%CI[10.1m-22.8m]). Since among the 74 first evaluable patients, 37 PFS
events occurred in the first year post-treatment, a 1-year PFS rate of ฀45% could not be rejected (p-
value=0.23). At an extended follow-up (32.6m median), 37 deaths have been recorded, with a median
OS 38.8m(95%CI[26.8m-Not Estimable]) and a 2-year OS rate of 63.7% (95%CI[51.9%-73.4%]). The OS
of stage IIIA patients was found to be significantly higher than stage IIIB patients, with 2-year OS 81%
and 56% respectively (p=0.037). Conclusion: PFS and OS are arithmetically higher to studies in the
same population, however, based on the formal hierarchical efficacy analysis, we could not reject that the
1-year PFS rate is ฀45%.
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Background: NICOLAS is the first completed single-arm phase II trial in stage III NSCLC examining hierarchically 
first the safety and then the efficacy of adding nivolumab concurrently to standard definitive concurrent 
chemo-radiotherapy. The safety endpoint was reported earlier; here we present the efficacy results. 
Methods: Stage IIIA/B unresectable treatment-naive NSCLC patients received 3 cycles of platinum-based 
chemotherapy and concurrent radiotherapy (66Gy/33fractions), along with nivolumab (360mg/Q3W). 
Nivolumab was continued as monotherapy consolidation for a maximum of one year (480mg/Q4W). The 
primary endpoint was 1-year PFS, with a target improvement compared to historical data of at least 15%, from 
45% to 60%. For testing this efficacy hypothesis, a sample size of 74 evaluable patients provides power 83%, at 
1-sided alpha 5%. 
Findings: 79 patients were enrolled with median follow-up 21.0 months (m) (Interquartile Range:15.8m-25.8m) 
for the primary PFS analysis. 35.4% of patients had stage IIIA and 63.3% stage IIIB. The 1-year PFS was 53.7% 
(95%CI[42.0%-64.0%]), the median PFS 12.7m (95%CI[10.1m-22.8m]). Since among the 74 first evaluable 
patients, 37 PFS events occurred in the first year post-treatment, a 1-year PFS rate of ≤45% could not be 
rejected (p-value=0.23). At an extended follow-up (32.6m median), 37 deaths have been recorded, with a 
median OS 38.8m(95%CI[26.8m-Not Estimable]) and a 2-year OS rate of 63.7% (95%CI[51.9%-73.4%]). The OS 
of stage IIIA patients was found to be significantly higher than stage IIIB patients, with 2-year OS 81% and 56% 
respectively (p=0.037). 
Conclusion: PFS and OS are arithmetically higher to studies in the same population, however, based on the 













Stage III non-small cell lung cancer (NSCLC) represent approximately 25% of all NSCLC patients at diagnosis.1 
The treatment of choice for fit patients with unresectable or multi-level N2 or any N3 disease is concurrent 
chemo-radiotherapy (CCRT).1 The combination of a platinum-based doublet chemotherapy given together with 
60-66 Gy in 2 Gy fractions of radiotherapy is considered standard of care.1 Although in highly selected patients, 
the five-year overall survival (OS) may reach up to 33%,2,3 most series report a more sobering 25% OS rate.4,5 
These inter-trial differences may be due to patient selection, as stage III NSCLCs represents an extremely 
heterogeneous group of diseases. 
The addition of 1 year of durvalumab after completion of CCRT has recently shown to improve 3-year OS by 
more than 10%.6 However, as most patients still suffer from disease recurrence, with a subsequent 57% 
survival rate at 3 years in that study, further improvements are still necessary. 
The concurrent administration of an anti-PD(L)-1 with radiotherapy may improve the response rate in 
preclinical models,7 with some synergy suggested in retrospective datasets.8,9 Similarly, in metastatic patients, 
concurrent platinum-based chemotherapy and anti-PD-(L)1 is the treatment of choice in all frontline stage IV 
patients irrespective of any biomarker, including patients with NSCLC characterized by a low PD-L1 
expression.10 
The concurrent administration of immune checkpoint inhibitors with CCRT, followed by 12 months of 
consolidation is a rational approach that ultimately may improve the OS over CCRT followed by durvalumab. 
The NICOLAS single-arm phase II trial combined nivolumab delivered for the first time concurrently with 
standard CCRT, using definitive radiation with standard fractionation doses, followed by a maximum of 
12 months of nivolumab consolidation therapy. 
We hierarchically tested the safety and efficacy of this regimen. The safety analysis has been reported earlier.  
Here, we report the results of the hierarchically tested primary endpoint of 1-year progression-free survival 

















The trial included patients from 10 European centres in five countries (Belgium, Germany, Spain, Switzerland 
and The Netherlands). 
Patient eligibility criteria included, as previously reported,11 age ≥18 years, pathologically confirmed locally 
advanced stage IIIA/B NSCLC (7th TNM classification), nodal status N2 or N3, Eastern Cooperative Oncology 
Group (ECOG) performance status 0-1, life expectancy greater than three months, as well as adequate 
haematological, liver and renal function. Patients with prior chemo-, radio- or molecular targeted therapy, or 
mixed small and non-small-cell histologic features were excluded.  
 
Trial design and treatment administration 
The history of the trial, and corresponding amendments have been previously described in detail.11 Protocol 
version 3.0 (v3) called for an efficacy evaluation focusing on only the patients receiving nivolumab concurrently 
with CCRT (supplement, Figure 1). Beyond the safety evaluation, the additional aim was to explore through a 
hierarchical design, the efficacy of the combination treatment. A corresponding increase of sample size was 
planned to enable the efficacy analysis in 74 evaluable patients. The primary efficacy endpoint, 1-year PFS rate, 
was designed to be tested, only conditional on proven adequate safety of the concurrent addition of nivolumab 
to chemo-radiotherapy. 
Three cycles of chemotherapy with cisplatin or carboplatin combined with either vinorelbine, etoposide or 
pemetrexed (non-squamous histology) were required. Delivery of the first induction cycle of platinum-based 
chemotherapy before inclusion in the trial was part of the protocol, in order to homogenize treatment and take 
into account potential radiotherapy planning delays in some participating centres. Radiotherapy, 66 Gy in 33 
once-daily fractions to the primary tumour and the involved lymph nodes,12 was delivered concurrently with 
the second and third chemotherapy cycle. Patients received four doses of nivolumab of 360 mg at a three-
week cycle, the first two concurrently with standard platinum-based chemotherapy and radiotherapy, starting 
from the first day of chemo-radiotherapy, followed by 480 mg at a four-week cycle for up to one year from 
start of nivolumab treatment. 
Ethics committees and relevant health authorities approved the trial protocol. This trial was registered with 















The primary endpoint, to be hierarchically tested after safety was proven, was PFS rate at 1-year. Start date for 
time-to-event endpoints was the date of 1st chemotherapy cycle. PFS was defined as the time from start date 
until a documented progression of disease according to RECIST v1.1 or death, if no documented progression 
had occurred. Tumour assessments by CT scans were performed every 9 weeks for the first year from 
enrolment, every 12 weeks for the second year and every six months afterwards. 
Secondary endpoints were OS (time from start date to death from any cause), objective response (OR) rate of 
patients, according to RECIST v1.1 criteria (best overall response, complete (CR) or partial response (PR), across 
all assessment time-points from enrolment to termination of protocol treatment), duration of response (DoR) 
(time from first OR documentation until documented progression), time-to-treatment failure (TTF) (time from 
enrolment until any kind of treatment failure, including discontinuation due to toxicity, progression, death, 
withdrawal or lost-to-follow-up) and time to first pneumonitis incidence of grade ≥3 (time from enrolment until 
first such documented pneumonitis). 
 
Statistical analysis 
According to the hierarchical design of the trial, the efficacy hypothesis would be tested only if the safety null 
hypothesis was rejected, either at the interim or the final safety analysis. This condition was satisfied, since the 
safety null hypothesis has been rejected at the interim analysis, as previously published.11 
The aim of the efficacy testing was to detect an increase in the 1-year PFS rate from ≤45% (P0) to at least 60% 
(P1) under concurrent nivolumab administration with CCRT. Using a 5% one-sided type I error and 83% power, a 
sample size of 74 patients was needed for testing this efficacy hypothesis according to the exact binomial test 
for single proportion. At least 41 out of the 74 patients had to reach one year without a PFS event in order to 
reject the null hypothesis. No formal efficacy interim analysis was planned for the trial. 
The event date for PFS was the first of either the imaging date of the first tumour assessment (TA) showing 
progression of disease (PD) or the date of death. Censoring date for PFS was the last TA date without event, 
while for OS, the date of last available contact with the patient while still alive. The estimation of all time-to-













Further analysis of PFS, OS and other secondary efficacy endpoints was performed on all patients enrolled in 
the CCRT cohort, while adverse events (AE) classified according to the CTCAE v4.0, are presented for the safety 
cohort. More details on statistical analysis are provided in the supplement.  
All statistical results were produced using SAS version 9.4. 
Interim safety analyses were performed in three-month intervals and reviewed by the European Thoracic 




The primary efficacy analysis was performed on the cohort consisting of the first 74 evaluable patients on 
CCRT, up to the primary efficacy analysis cut-off of August 2019. These patients had either reached 1-year 
tumour assessment without a PFS event or had earlier experienced a PFS event. For completeness purposes, all 
other results except for the primary analysis are presented for all 79 patients on the CCRT regimen (full CCRT 
cohort, Figure 1). This cohort includes all patients enrolled on CCRT, irrespective of whether they received any 
dose of study treatment (intention-to-treat population). The safety cohort consists of the 77 patients who 
received at least one dose of treatment after enrolment.  
 
Patient and treatment characteristics 
A total of 79 patients were enrolled in the study from 14/09/2016 to 6/08/2018. The patient and treatment 
characteristics for the full CCRT cohort are presented in Table 1. The median follow-up of 21 months 
(Interquartile Range (IQR): 15.8m-25.8m) captures all follow-up up to completion of one year on study of the 
last enrolled patient, (database cut-off: 21 August 2019; queried/final: 18 September 2019).  
Of the 79 NICOLAS patients in the full cohort, 77 started protocol treatment (two died before treatment start). 
The median age of patients was 62 years [IQR: 41-78], the majority were male (67.1%), had non-squamous 
histology (59.5%) and stage IIIB (63.3%), were former smokers (68.4%), and with ECOG PS at enrolment of 1 
(51.9%). Chemotherapy constituted cisplatin-based combination with etoposide, pemetrexed or vinorelbine in 
65 (84.0%) patients while a carboplatin-based combination was used for 12 patients (15%). After completion of 













All three chemotherapy cycles were completed for 73 and radiotherapy (at least 60 Gy) for 72 patients. Per 
protocol, treatment of nivolumab was completed successfully in 31 patients (39.2%). The overall median 
number of nivolumab doses was 11 (IQR: 1-15). From the total of 46 treatment discontinuations, five occurred 
during the CCRT-nivolumab phase (two toxicities: stroke and febrile neutropenia; two disease progressions and 
one investigator’s decision). For the 41 treatment discontinuations during the nivolumab-alone phase, 
recorded reasons were 18 toxicities, 18 progressions, two deaths, one withdrawal, one investigator’s decision, 
and one unspecified (a patient for longer than six weeks without treatment). Forty-nine (62%) patients were 
still on follow-up at final analysis time.  
 
Primary efficacy analysis: 1-year PFS 
As previously mentioned, the 1-year PFS analysis was based on the primary efficacy analysis cohort, which 
according to the design includes the first 74 evaluable patients who either completed 1-year of follow-up 
without an event or had a PFS event up to the 1-year time-point. This cohort does not take into consideration 
two patients who died before treatment start, one who withdrew 2.6 months after enrolment as well as the 
last two enrolled patients who reached 1-year follow-up later. To reject the null efficacy hypothesis, at least 41 
patients from a total of 74 patients on CCRT treatment, should have reached 1-year progression free. The 
required number was not reached. Only 37 patients were free of progression at one year. Thus, the null 
hypothesis of 1-year PFS rate ≤45% could not be rejected (exact binomial test p-value=0.23). If the analysis 
takes into account the two patients who died before treatment and/or the withdrawn patient, the conclusion 
remains the same.  
For the primary efficacy cohort of 74 patients, the estimated from the Kaplan-Meier curve PFS at 1-year is 
50.0% (95%CI [39.9%-60.1%]) (Figure S1). 
 
Secondary analyses (full CCRT cohort) 
Progression-free Survival  
Among all the 79 patients enrolled in the CCRT regimen, 49 (62.0%) PFS events were observed, with 40 
occurring by 1 year. Progression was documented for 36 patients, with 15 of them subsequently dying, while 
13 patients died without documented progression (with reason of death: lung cancer (3), stroke (2), 













[42.0%-64.0%]) and median PFS is 12.7 months (95%CI [10.1m-22.8m])(Figure 2a). For the 28 patients with 
squamous histology, 20 (71.4%) PFS events were recorded with 1-year PFS of 53.6% (95%CI [33.8%-69.8%]) and 
a median PFS of 12.7 months (95%CI [10.1m-22.8m]), while among the 47 non-squamous histology patients, 26 
(55.3%) events occurred, with 1-year PFS of 54.4% (95%CI [39.1%-67.4%]) and median 12.4 months (95%CI 
[7.2m-NE]) (Figure S2A). Fourteen (50.0%) PFS events were recorded among the 28 stage IIIA patients (1-year 
PFS: 62.6%, 95%CI [41.6%-77.9%]; median PFS of 27.4 months, 95%CI [7.2m-NE]) and 34 (68.0%) events out of 
the 50 stage IIIB patients (1-year PFS: 50.0%, 95%CI [35.6%-62.8%]; median 12.1 months, 95%CI [8.9m-17.8m]) 
(Figure S2B). Statistically significant differences were not observed, neither between the histology nor between 
the stage subgroups (p-value=0.59 and 0.11, respectively). 
None of the variables examined in univariate or multivariate Cox models yielded any statistically significant 
effect on PFS (all p-values>>0.05) (Figures 2b, S2). 
 
Overall survival  
OS results are presented here as of September 2020, analysed beyond the cut-off for the primary PFS analysis, 
with a median follow-up of 32.6 months (IQR: 26.3m-39.4m). Among the 79 patients, 37 (46.8%) deaths were 
observed, with a median OS of 38.8 months (95%CI [26.8m-NE]), 1-year OS rate 75.7% (95%CI[64.6%-83.7%] 
and 2-year OS rate 63.7% (95%CI[51.9%-73.4%]). Most deaths (20; 54.1%) were attributed to lung cancer and 
one to toxicity (pneumonitis along with tumour progression), while other reported reasons included stroke 
(n=2), sepsis, cardiac, oesophageal ulcer with haemorrhage, myelodysplastic syndrome, pericarditis 
carcinomatosa, pneumonia, pulmonary embolism (uncertain whether it was death due to pulmonary fibrosis or 
myocarditis), necrotizing colitis and severe anaemia (one each). Death reason was not reported for five cases. 
Relation to treatment was assessed for the deaths recorded as adverse events (8 fatal adverse events at least 
possibly related to one of the treatments administered). 
In univariate analyses, no statistically significant difference in OS was found between the histological subgroups 
(p-value=0.35; Figure 3A) or other variables, except for stage when comparing stage IIIA to IIIB (log-rank p-
value=0.037; Figure 3B). Eight (28.6%) deaths occurred among the 28 stage IIIA patients with 2-year OS of 
81.0% (95%CI [60.1%-91.7%]) and 28 (56.0%) deaths among the 50 stage IIIB patients with 2-year OS of 55.6% 
(95%CI [40.8%-68.2%]). The median OS was 28.6 months for the IIIB patient subgroup (95%CI [12.8m-41.4m]), 













In the multivariate Cox model, stage remains significant (Cox Wald p-value=0.029), along with age (p-
value=0.046) (Figures 3, S3). 
Objective response rate  
The ORR was 73.4% (95%CI [62.3%-82.7%]), with five (6.3%) CRs. For five patients only the baseline tumour 
assessment was available before treatment discontinuation. For the 58 patients with documented OR, the 
median DoR was 11.0 months (95%CI [8.6m-20.7m]) with 33 (56.9%) of them progressing afterwards 
(Figure S4). Sixty out of 79 patients (76.0%) achieved at least a partial remission of their target lesions. with 58 
of them achieving objective response (53 PR, 5 CR; RECIST v1.1), during treatment. Change from baseline for 
targeted lesion size is presented in Figure 4.  
 
Time to treatment failure 
In total, 58 (73.4%) treatment failures were observed with 1-year TTF of 41.8% (95%CI [30.8%-52.3%]) and 
median 9.2 months (95%CI [6.4m-12.4m]). For 10 (32.3%) of the 31 patients who completed the 1-year 
nivolumab per-protocol, failure was due to progression (7 patients), death (2 patients) or withdrawal 
(1 patient).  
 
Time to first pneumonitis of grade≥3 (TFP3) 
Nine (11.7%) pneumonitis events of grade≥3 occurred among the 79 patients. All occurred within 1-year of 
follow-up, with corresponding 1-year TFP3 of 87.0% (95%CI [76.4%-93.0%]; median: NE) (Table S1). 
 
Site of progression and tumour change  
In the majority of the 36 documented progressions (27; 75.0%) distant metastases (appearance of new lesions) 
were recorded (among them seven cases (19.4%) involved also local and/or regional progression), three cases 
were local metastases, while from the remaining six cases, three were loco-regional only, two were local and 
one was regional PD. 
Metastases were detected in only one site for 21 patients (70.0% of the 30 patients with distant/local 
metastases), while in two and three sites in 8 (26.7%) and 1 (3.3%) patients, respectively. The lungs were the 
most frequent metastatic site (25.0%), followed by the brain (17.5%), the lymph nodes (15.0%) and the liver 
















The safety cohort consisted of the 77 patients who received at least one dose of treatment, with 76 (98.7%) of 
them experiencing at least one adverse event (AE). A detailed display of the AEs by grade is provided in Table 
S4. 
Of the total number of 780 AEs, 91 (11.6%) were severe, 20 (2.6%) life-threatening and 10 (1.3%) fatal 
(Table 2). Seven of the 10 fatal events, are considered at least possibly related to nivolumab, with pneumonitis 
definitely attributed to nivolumab and possibly related to RT, while oesophageal fistula is definitely related to 
RT.  
In total, 361 AEs were related to at least one treatment, with 168 (21.5%) related to RT, and 249 (31.9%) to 
nivolumab (Table 2). For 84.5% of these (radiotherapy- or nivolumab-related) events, no action was taken, 
while for 31 (8.6%), dose was delayed. Only in eight (2.2%) cases the dose was temporarily discontinued and in 
16 (4.4%) permanently (one of grade 1, nine of grade 2, five of grade 3, one of grade 5). For 1.6% of cases, no 
information on the action taken was available.  
 
Serious adverse events 
Almost half of the patients in the safety cohort experienced from one to four serious AEs (SAEs) (48.1%). Of the 
total 61 recorded SAEs, 15 (24.6%) were of grade 2, 29 (47.5%) of grade 3, and eight each for grade 4 (life-
threatening) and grade 5 (fatal). Most of them were resolved (75.4%). Only four (6.6%) were attributed to 
nivolumab. 
In total, nine (11.7%) patients experienced a pneumonitis event of grade≥3 (eight of grade 3 and one of 
grade 5), six of which occurred within 6 months post RT. Seven were resolved completely, one was resolved 
with sequelae, while one more although initially resolved, re-occurred leading to the patient’s death. The 
median time to event’s resolution was 11 days (range: 6-53). All pneumonitis cases were attributed to 
nivolumab (three with possible, four with probable and two with definite relation) while, four cases were also 















Radical, curative-intent, treatment of stage III NSCLC, while extensively studied has remained a medical 
challenge. While concurrent chemo-radiotherapy has been the standard of care for inoperable disease for a 
long time, the results of the recent PACIFIC study has defined a new standard by combining CCRT with 
consolidation durvalumab for 12 months. Despite these clinically meaningful advances, the majority of patients 
will eventually still die from lung cancer.6,13 As there is preclinical evidence that the administration of a PD(L)-1 
antagonist immediately after or preferably during radiotherapy may be the most efficient7 way to combine 
treatment, the NICOLAS trial investigated the concurrent administration of nivolumab with CCRT followed by 
12 months of nivolumab. In this trial, we report for the CCRT cohort, a 1-year PFS of 53.7%, a median PFS 12.7 
months, a 1-year OS 75.7%, 2-year OS 63.7% and a median OS 38.8 months.  
These results could also be viewed in relation to other recent studies such as RTOG 0617,2 PROCLAIM5 and 
PACIFIC6 (Tables S5, S6). The 1-year PFS was 48% in the 60 Gy arm of RTOG 0617, 48% in the cisplatin-
pemetrexed arm of PROCLAIM and 55.9% in the durvalumab arm of PACIFIC. The 1-year OS and median OS for 
RTOG 0617, PROCLAIM and PACIFIC were 78%, 76%, 83.1% and 28.7 months, 26.8 months, not reached, 
respectively (at median follow-up times 32.4, 22.2 and 33.3 months accordingly). However, major differences 
between these studies should be emphasized, using significantly distinct upfront selection criteria. In PACIFIC, 
patients were randomized after having received CCRT, which is 2-3 months later than in the other studies 
RTOG, PROCLAIM and NICOLAS, all of which included patients before CCRT. In PACIFIC, only the fittest patients 
without disease progression after completion of CCRT were enrolled, whereas in NICOLAS, similarly to RTOG 
0617 and PROCLAIM, patients had to be in a good general condition at time of enrolment, before starting CCRT. 
In PROCLAIM, only non-squamous histologies (mainly adenocarcinoma) were eligible in view of the use of 
pemetrexed. In the same study, patients with pleural effusion required a puncture. In case of documented 
exudate, even in the absence of malignant cells, patients were not eligible for the trial. In RTOG 0617, patients 
with involvement of supraclavicular lymph nodes were not eligible for the study. In this study, also pleural 
exudates were excluded, regardless of the cytology. Additionally, patients’ demographics also appear to be 
different between these studies. In NICOLAS, stage IIIB patients, generally characterized with a poorer 
outcome, were representing 63% of the ITT population, a substantially higher proportion than in PACIFIC (45%), 
RTOG 0617 (34%) and PROCLAIM (52%). As the inclusion criteria of the present NICOLAS trial were less 
stringent than in the two other studies, with a NSCLC population characterized with a possibly worse outcome, 













in RTOG 0617 and 38% in PROCLAIM as well as the median OS of 38.8 months compared to 28.7 and 26.8 
months respectively, support continuous investigations of concurrent immunotherapy with CCRT.  
As previously published, it is reassuring that the toxicity of nivolumab given together with CCRT was within the 
predefined limits.11 Of note, 89% of treatment discontinuations happened during the consolidation phase, with 
44% of them being attributed to treatment toxicity. While we could not reject that the 1-year PFS rate is 45% 
or lower, the safety, PFS and OS outcomes support continued investigation of concurrent nivolumab with CCRT. 
Ultimately, the impact of using immune checkpoint inhibition concomitantly to chemo-radiotherapy will be 
determined in larger randomized trials using durvalumab (NCT04092283, NCT03519971) or nivolumab 
(NCT04026412).  
In conclusion, at the present time, the use of checkpoint inhibitors given concurrently with CCRT remains 
experimental, but this strategy is promising enough to warrant further investigation. 
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Figure 1: Patient flowchart. 
* The primary efficacy analysis cohort consists of the first 74 evaluable patients under concurrent CRT who had 
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Figure 2: Progression-free survival. A) Progression-free survival (full CCRT cohort; N=79) (CI band is indicated with 
dashed lines). B) One-year progression-free survival rate by patient and treatment characteristics (Full CCRT 
cohort; N=79). All p-values from separate Cox models are not significant at α=5%. (Not shown: Never smokers n=3, 
Missing observations: histology n=4, stage n=1, ECOG PS n=1, chemotherapy regimen n=2) 
 
Figure 3: Overall survival by histology and stage  
A) Overall survival by histology. B) Overall survival by stage 
(Full CCRT cohort; N=79) Note: Missing: histology n=4; stage n=1 
 
Figure 4: Best % change from baseline for target lesion size (Sum of tumour diameters for targeted lesions) 
(Among patients with available information in the full CCRT cohort; N=79)  









Table 1: Patient and treatment characteristics (full CCRT cohort; N=79) 
Characteristic All patients  
Before treatment start (N=79) 
Age (years) 
n (%) 79 (100.0) 
Mean (95% CI) 62.3 (60.3, 64.3) 
Median (Min-Max) 62 (41 - 78) 
Gender - n (%) 
Male 53 (67.1) 
Female 26 (32.9) 
Histology - n (%)  
Non-squamous 47 (59.5) 
Squamous  28 (35.4) 
Missing 4 (5.1) 
Stage - n (%) 
IIIA 28 (35.4) 
IIIB 50 (63.3) 
Missing 1 (1.3) 
Smoking history - n (%) 
Current (patient still smokes) 22 (27.8) 
Former (≥100 cigarettes in the past during the whole life) 54 (68.4) 
Never (0-99 cigarettes during the whole life) 3 (3.8) 
ECOG Performance status at enrollment - n (%) 
0 37 (46.8) 
1 41 (51.9) 
Unknown/Missing 1 (1.3) 
After treatment start (N=77) 
Chemotherapy regimen - n (%) 
Cisplatin  
Etoposide 24 (31.2) 
Pemetrexed 20 (26.0) 
Vinorelbine 21 (27.3) 
Carboplatin (Etoposide/Pemetrexed/Vinorelbine) 12 (15.6) 
ECOG Performance status after CRT phase - n (%) 
0 26 (33.8) 
1 42 (54.6) 
2 3 (3.9) 
3 1 (1.3) 
4 1 (1.3) 










Table 2: Treatment related adverse events (safety cohort; N=77) 
 
Radiotherapy Nivolumab 
 n (%) 
Safety cohort 77 76 
Any AE (SAE) 780 (61) 
Treatment related AEs (SAEs) 168 (14) 249 (26) 
Treatment related AEs (SAEs) Grade 3-5 32 (9) 44 (18) 
Treatment related AEs (SAEs) leading to death 2 (1) 7 (6) 
Treatment related AEs (SAEs) leading to treatment permanent discontinuation 6 (-) 16 (-) 
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